GlassScriptPhysician profile
Adam W Cerel
NPI 1467441857
$16,286.87
in general payments reported to CMS, 2019-2025
42 companies · $2,656 in 2025
The $2,656 reported for 2025 was more than what 87% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $2,988 · 2020: $2,039 · 2021: $2,109 · 2022: $2,603 · 2023: $2,061 · 2024: $1,832 · 2025: $2,656.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,876 · Consulting Fee: $650 · Education: $21.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,876.48 |
| Consulting Fee | $650.00 |
| Education | $21.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,243.83 | 2019-2024 | Xarelto |
| Pfizer INC. | $1,846.63 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,587.50 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,515.99 | 2019-2025 | Farxiga, Breztri |
| Amgen INC. | $1,368.20 | 2019-2025 | Repatha, Repatha |
| Sanofi-Aventis U.S. LLC | $1,352.82 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $620.06 | 2021-2025 | Verquvo, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $604.71 | 2019-2025 | Jardiance |
| Anumana, INC. | $600.00 | 2025 | Ecg-Ai Lef |
| Glaxosmithkline, LLC. | $571.10 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amarin Pharma, INC. | $485.96 | 2019-2022 | |
| Novo Nordisk INC | $395.76 | 2019-2025 | Wegovy, Ozempic |
| E.R. Squibb & Sons, L.L.C. | $390.49 | 2019-2025 | Eliquis, Camzyos |
| Kiniksa Pharmaceuticals, LTD. | $290.18 | 2021-2023 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $258.09 | 2019-2022 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $220.45 | 2024-2025 | |
| Bardy Diagnostics, INC. | $207.35 | 2019-2021 | |
| Kiniksa Pharmaceuticals International, Plc | $195.14 | 2024 | Arcalyst |
| Esperion Therapeutics, INC. | $190.91 | 2020-2025 | Nexletol |
| Baxter Healthcare | $165.08 | 2023-2025 | Hillrom - Carnation Ambulatory Monitor |
| Boston Scientific Corporation | $149.17 | 2019-2024 | Lux-Dx Insertable Cardiac Monitor |
| Kowa Pharmaceuticals America, INC. | $145.98 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $144.70 | 2023-2025 | |
| Heartflow, INC. | $112.25 | 2024-2025 | |
| Alnylam Pharmaceuticals INC. | $93.05 | 2025 | Onpattro, Amvuttra |
| Medtronic, INC. | $75.00 | 2021-2025 | Sprinter Legend |
| United Therapeutics Corporation | $55.08 | 2025 | Tyvaso |
| Altathera Pharmaceuticals LLC | $50.87 | 2023-2025 | Sotalol Hydrochloride |
| Infobionic, INC | $42.98 | 2019 | |
| Eisai INC. | $38.62 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.43 | 2019 | |
| Janssen Scientific Affairs, LLC | $31.23 | 2024 | Xarelto |
| Inogen, INC. | $31.12 | 2024-2025 | |
| Inspire Medical Systems, INC. | $27.72 | 2025 | Inspire |
| Rgh Enterprises LLC | $23.98 | 2023 | |
| Exact Sciences Corporation | $22.24 | 2023 | Cologuard Collection Kit |
| Vital Connect, INC | $21.71 | 2024 | Vitalpatch Rtm |
| Lexicon Pharmaceuticals, INC. | $21.45 | 2024 | |
| Lilly USA, LLC | $21.01 | 2023 | Mounjaro |
| Braemar Manufacturing, LLC | $19.74 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $12.29 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,605.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Cerel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.